Another example is the FDA approved sipuleucel‐T for prostate cancer immunotherapy, where the design approach was used to develop the lapuleucel‐T vaccine for bladder cancer immunotherapy, using HER2 instead of PSMA for specific targeting 200. This evidence concerns the gene FOLH1 and prostate cancer.